drug
Relexxii
Marketedupdated 3mo agoby Vertical Pharmaceuticals LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval408 co-mentions · 201 sources
- drugMETADATE CD384 co-mentions · 206 sources
- drugMETADATE ER251 co-mentions · 206 sources
- drugRITALIN LA234 co-mentions · 206 sources
- drugQuillivant XR223 co-mentions · 206 sources
- drugMETHYLIN ER222 co-mentions · 206 sources
- drugMethylin222 co-mentions · 206 sources
- drugmethylphenidate hydrochloride ER214 co-mentions · 206 sources
all catalysts(0)
nothing on the calendar yet
Trials studying Relexxii
- phase3Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD
- phase1Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions
- phase1Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions
- phase4A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 3, 2037
~10.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (35)
- Feb 3, 2037formulationUS 10265308
- Feb 3, 2037formulationUS 10265308
- Feb 3, 2037formulationUS 10265308
- Feb 3, 2037formulationUS 10265308
- Feb 3, 2037formulationUS 10265308
- Feb 3, 2037formulationUS 10265308
- Feb 3, 2037formulationUS 10265308
- Feb 3, 2037method-of-use (U-4032)US 10695336
- Feb 3, 2037method-of-use (U-4032)US 10695336
- Feb 3, 2037method-of-use (U-4032)US 10695336
- Feb 3, 2037method-of-use (U-4032)US 10695336
- Feb 3, 2037method-of-use (U-4032)US 10695336
- Feb 3, 2037method-of-use (U-4032)US 10695336
- Feb 3, 2037method-of-use (U-4032)US 10695336
- Feb 3, 2037formulationUS 9707217
- Feb 3, 2037formulationUS 9707217
- Feb 3, 2037formulationUS 9707217
- Feb 3, 2037formulationUS 9707217
- Feb 3, 2037formulationUS 9707217
- Feb 3, 2037formulationUS 9707217
- Feb 3, 2037formulationUS 9707217
- Feb 3, 2037method-of-use (U-4032)US 9827234
- Feb 3, 2037method-of-use (U-4032)US 9827234
- Feb 3, 2037method-of-use (U-4032)US 9827234
- Feb 3, 2037method-of-use (U-4032)US 9827234
- Feb 3, 2037method-of-use (U-4032)US 9827234
- Feb 3, 2037method-of-use (U-4032)US 9827234
- Feb 3, 2037method-of-use (U-4032)US 9827234
- Feb 3, 2037formulationUS 9855258
- Feb 3, 2037formulationUS 9855258
- Feb 3, 2037formulationUS 9855258
- Feb 3, 2037formulationUS 9855258
- Feb 3, 2037formulationUS 9855258
- Feb 3, 2037formulationUS 9855258
- Feb 3, 2037formulationUS 9855258
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that